Filtered By:
Specialty: Neurosurgery

This page shows you your search results in order of date. This is page number 20.

Order by Relevance | Date

Total 602 results found since Jan 2013.

Regional efficacy of natalizumab treatment in relapsing-remitting multiple sclerosis (rrms)
Discussion The data confirms in a typical UK clinical setting good treatment response was achieved in highly active RRMS patients using Natalizumab. No additional factors were found which could predict treatment response suggesting within the limitations of power and length of this study that Natalizumab is effective in a broad range of highly active RRMS patients.
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Doshi, A., Voysey, Z., Bunting, E., Malik, M., Rashid, W. Tags: Immunology (including allergy), Multiple sclerosis Thur 21, Parallel session 5: Therapeutics Source Type: research

Thyrotoxicosis secondary to alemtuzumab treatment for multiple sclerosis presenting as pulmonary hypertension
We present the case of a 31-year-old female patient who presented with signs consistent with pulmonary hypertension as the presenting feature of thyrotoxicosis. 12-months after the first alemtuzumab treatment course the patient presented to clinic with a 2-week history of exertional dyspnoea, palpitations and headaches. On examination, she had a new pansystolic murmur loudest in the pulmonary area and bilateral pitting oedema to the knees. An echocardiogram demonstrated elevated right ventricular pressure (40 mm Hg) and tricuspid regurgitation consistent with pulmonary hypertension. A CT pulmonary angiogram did not demonst...
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Healy, S., Willis, M., Pickersgill, T., Page, M., Robertson, N. Tags: Immunology (including allergy), Drugs: CNS (not psychiatric), Headache (including migraine), Multiple sclerosis, Pain (neurology), Hypertension Thur 21, Parallel session 5: Therapeutics Source Type: research

The physical, social & economic extent of multiple sclerosis in sussex
This study highlights the needs of people with MS in Sussex. Of note is the impact on employment and the need for walking aids and additional care associated with MS. This knowledge will allow us to better develop services for people with MS with commissioners.
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Howells, J., Rashid, W. Tags: Immunology (including allergy), Multiple sclerosis Thur 21, Parallel session 5: Therapeutics Source Type: research

Long-term safety of alemtuzumab in relapsing-remitting multiple sclerosis: pregnancy and infection data from a cohort of patients on open label studies in cambridge
Conclusions During prolonged follow-up of this cohort of patients treated with alemtuzumab no serious infections occurred. No increased risk of miscarriage or foetal abnormality was seen in the small number of pregnancies studied.
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: McCarthy, C., Tuohy, O., Azzopardi, L., Kousin-Ezewu, O., Jones, J., Compston, A., Coles, A. Tags: Immunology (including allergy), Multiple sclerosis Thur 21, Parallel session 5: Therapeutics Source Type: research

Management of fingolimod first dose observation (fdo) in the uk
Conclusion 96% of 1013 fingolimod patients were discharged at 6-hours post-first dose. No patients required pharmacological intervention.
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Pamies, P., Webber, B., Pull, E. Tags: Immunology (including allergy), Multiple sclerosis, Hypertension Thur 21, Parallel session 5: Therapeutics Source Type: research

Effect of fingolimod vs. ifn-beta1a on no evidence of disease activity
Conclusion Fingolimod-treated patients had twice the odds of achieving NEDA-4 status over 1 year as patients treated with IFN.
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Silber, E., Montalban, X., Barkhof, F., Khatri, B., Hartung, H., Ritter, S., Meier, D. P., Tomic, D., Kappos, L. Tags: Immunology (including allergy), Multiple sclerosis Thur 21, Parallel session 5: Therapeutics Source Type: research

Single centre randomised pilot study of two regimens (30 mins daily or 30 mins weekly for 12 weeks) of transcutaneous tibial nerve stimulation using a novel device for treating multiple sclerosis-related overactive bladder symptoms
Introduction Percutaneous tibial nerve stimulation (PTNS) is effective for managing multiple sclerosis (MS)-related overactive bladder (OAB) symptoms. However the need for weekly clinic visits restricts its use. The purpose of this study was to evaluate safety and efficacy of a novel, self-applying device for managing OAB symptoms. Study design, materials and methods 48 patients reporting OAB (MS n=24, idiopathic n=24), were randomized (1:1) to either daily or weekly treatments for 12 weeks with geko™, a novel device stimulating the tibial nerve transcutaneously. Efficacy was assessed using validated questionnaires ...
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Seth, J., Haslam, C., Gonzales, G., Pakzad, M., Vashisht, A., Elneil, S., Sahai, A., Knowles, C., Tucker, A., Panicker, J. Tags: Immunology (including allergy), Drugs: CNS (not psychiatric), Multiple sclerosis Thur 21, Parallel session 5: Therapeutics Source Type: research

Early prediction of long-term response to natalizumab in multiple sclerosis
Conclusions Relapses and new MRI activity within the first year of starting natalizumab predict short-term outcomes, but not long-term disability outcomes. This requires further validation in other cohorts.
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Raffel, J., Gafson, A., Dahdaleh, S., Nicholas, R. Tags: Immunology (including allergy), Multiple sclerosis Thur 21, Parallel session 5: Therapeutics Source Type: research

Management of adverse reactions to alemtuzumab infusion
In the 2-year, phase 3 CARE-MS studies of alemtuzumab in patients with relapsing-remitting multiple sclerosis, infusion-associated reactions (IARs) were the most common adverse events. Here we report on IARs during 4-year follow-up. Patients who were treatment-naive (CARE-MS I; NCT00530348) or with inadequate efficacy response to prior therapy (CARE-MS II; NCT00548405) received 2 annual courses of alemtuzumab 12 mg, and as-needed retreatment in an extension study (NCT00930553). Patients received methylprednisolone on the first 3 days of each course. IARs were any adverse event occurring between start of infusion and w...
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Sharrack, B., Mayer, L., Coles, A., Hartung, H.-P., Havrdova, E., Selmaj, K., Margolin, D., Compston, A. Tags: Immunology (including allergy), Headache (including migraine), Multiple sclerosis, Pain (neurology) Thur 21, Parallel session 5: Therapeutics Source Type: research

Effect of teriflunomide on lymphocyte and neutrophil counts
Conclusions These data demonstrate that teriflunomide has small, reversible effects on lymphocyte/neutrophil counts, with no increase in infection risk observed. (Study supported by Genzyme, a Sanofi company).
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Weller, B., Comi, G., Freedman, M., Kappos, L., Miller, A., Olsson, T., Wolinsky, J., Benamor, M., Truffinet, P., O'Connor, P. Tags: Immunology (including allergy), Drugs: musculoskeletal and joint diseases Thur 21, Parallel session 5: Therapeutics Source Type: research

Safety and tolerability of teriflunomide in clinical studies
Conclusions These data from >6800 patient-years of teriflunomide exposure were consistent with individual studies and no new, unexpected safety signals were observed. (Study supported by Genzyme, a Sanofi company).
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Barnes, D., Leist, T., Freedman, M., Olsson, T., Miller, A., Wolinsky, J., O'Connor, P., Benamor, M., Truffinet, P., Comi, G. Tags: Immunology (including allergy), Multiple sclerosis Thur 21, Parallel session 5: Therapeutics Source Type: research

Analysis of the topic study using 2010 mcdonald criteria
Conclusions Teriflunomide demonstrates a consistent treatment effect in patients with MS diagnosed according to differing diagnostic criteria. (Study supported by Genzyme, a Sanofi company).
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Rog, D., Wolinsky, J., Truffinet, P., Thangavelu, K., Miller, A. Tags: Immunology (including allergy), Multiple sclerosis, Radiology, Radiology (diagnostics) Thur 21, Parallel session 5: Therapeutics Source Type: research

Long-term treatment of relapsing-remitting multiple sclerosis with interferon {beta}: how strongly should we encourage patients to adhere to the 'old' therapies?
Current recommendations and guidelines for use of disease modifying drugs (DMDs) in relapsing-remitting multiple sclerosis refer to interferon β (IFNβ) and glatiramer acetate as injectables as well as the new orals teriflunomide, dimethyl fumarate (DMF) and also fingolimod, natalizumab and alemtuzumab. Several pivotal studies have demonstrated a short-term benefit for earlier treatment with DMDs on clinical and MRI activity but there are only limited data available from controlled studies on long-term clinical outcome including sustained accumulation of disability and conversion to secondary progression. Therapeu...
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Heidenreich, F. Tags: Immunology (including allergy), Multiple sclerosis Editorial commentaries Source Type: research

Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15
Conclusions These findings suggest that higher cumulative exposure to sc IFN β-1a may be associated with better clinical outcomes, and early change in EDSS score may have prognostic value, over many years, in RRMS.
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Kappos, L., Kuhle, J., Multanen, J., Kremenchutzky, M., Verdun di Cantogno, E., Cornelisse, P., Lehr, L., Casset-Semanaz, F., Issard, D., Uitdehaag, B. M. J., King, Barnett, Freedman, Oger, Sandberg-Wollheim, Constantinescu, Palace, Barnes, Williams, Dubo Tags: Open access, Immunology (including allergy), Multiple sclerosis Source Type: research

A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes
Conclusions A panel of nine CSF biomarkers was able to differentiate APS from patients with PD and dementia. This may have important clinical utility in improving diagnostic accuracy, allowing better prognostication and earlier access to potential disease-modifying therapies.
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Magdalinou, N. K., Paterson, R. W., Schott, J. M., Fox, N. C., Mummery, C., Blennow, K., Bhatia, K., Morris, H. R., Giunti, P., Warner, T. T., de Silva, R., Lees, A. J., Zetterberg, H. Tags: Immunology (including allergy), Cranial nerves, Dementia, Drugs: CNS (not psychiatric), Movement disorders (other than Parkinsons), Parkinson's disease, Ophthalmology, Memory disorders (psychiatry), Psychiatry of old age Neurodegeneration Source Type: research